Skip to content

Jeffrey W. Albers, Director at Spyre Therapeutics, sold SYRE on Aug 7, 2026

Data as of Oct 16

▼ SELL$835K8,000 shares at $104.38Jeffrey W. Albers DirectorSYRE Spyre Therapeutics, Inc.
Watch SYRE
Traded
Aug 7, 2026
Disclosed
Aug 10, 2026
Filed
3 days after the trade

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Jeffrey W. Albers, Director at Spyre Therapeutics, sold SYRE on Aug 7, 2026TRADEDDISCLOSED
SYRESimilar stocks (XLV — its sector index fund), rebased to SYRE's price on the disclosure day
SYRE since disclosure
−24.1%
after the sale
Similar stocks (XLV) since disclosure
+4.9%
XLV — its sector index fund

Change in closing price from Aug 10, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▼ SELLJeffrey W. Albers DirectorSYRE Spyre Therapeutics, Inc.$522Kdisclosed Aug 10 · filed 3 days after the trade
  2. ▼ SELLJeffrey W. Albers DirectorSYRE Spyre Therapeutics, Inc.$1Mdisclosed Aug 10 · filed 3 days after the trade

See every trade on SYRE →